Torrent Pharmaceuticals reported mixed Q4 results with consolidated net profit declining 21.9% year-on-year to ₹389 crore compared to ₹498 crore in the same period last year. However, revenue surged 41.8% to ₹4,197 crore from ₹2,959 crore, while EBITDA increased 40.7% to ₹1,356 crore from ₹964 crore. The company maintained a EBITDA margin of 32% compared to 33% in the year-ago period, as reported by CNBC TV18. The profit decline was primarily attributed to total expenses rising nearly 60% during the quarter, significantly outpacing revenue growth, with the increase driven by higher employee expenses, finance costs, and depreciation charges.
The India business demonstrated strong performance with revenue growing 43% to ₹2,215 crore and base business growth of 15%, outpacing IPM growth of 10% as per AIOCD PharmaTrac data. For the full fiscal year FY26, India revenues stood at ₹7,645 crore, up 20%, with the company noting that its base business remains among the fastest growing in the top 10 pharma firms. The Gx Semaglutide launch secured 38% market share (oral and injectable combined) as per April 26 PharmaTrac data, according to CNBC TV18 reports. The company has traditionally maintained a strong presence in therapeutic segments such as cardiovascular, central nervous system, gastrointestinal, women's healthcare, diabetology, pain management, and oncology, with strong demand in chronic therapies supporting domestic formulations revenue growth.
Brazil revenues rose 30% to ₹455 crore with constant currency revenues increasing 11% to R$ 259 million, as per IQVIA data. The company grew 17% versus market growth of 6%, supported by top brands and recent launches, with 58 products under ANVISA review. US revenues increased 31% to ₹396 crore with base business revenue rising 16% and constant currency revenue of $38 million, up 9%. For FY26, US revenues stood at ₹1,363 crore, up 24%, with base business growing 20%. In Germany, revenues rose 16% to ₹333 crore, though constant currency revenues declined 1% to €31 million due to supply disruptions at a third-party supplier, as reported by CNBC TV18.
The company has recommended obtaining enabling approval from shareholders to raise up to ₹5,000 crore through issuance of equity shares, including convertible bonds or debentures, via Qualified Institutional Placement (QIP) and/or other permitted modes at its upcoming Annual General Meeting. It has also recommended a final dividend of ₹9 per equity share of face value ₹5, equivalent to 180%, for FY26. If approved by shareholders, the dividend is expected to be paid or dispatched on or around June 25, 2026. Earlier, Torrent Pharmaceuticals had paid an interim dividend of ₹29 per equity share, equivalent to 580%, during the last quarter. Shares ended at ₹4,494.00, up by ₹23.15, or 0.52% on the BSE, as reported by CNBC TV18.
